Phase 2 N=41 Randomized Quadruple-blind Treatment

Cannabidiol Treatment of Cognitive Dysfunction in Schizophrenia

Schizophrenia · Schizoaffective Disorder

Bottom Line

View on ClinicalTrials.gov: NCT00588731 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2017

Primary outcome: Primary: Verbal Short Term Memory — 43.7; 37.9; 43.6; 40.8 t-score — p=0.90

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Cannabidiol (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Yale University
Primary completion: Dec 2013

Outcome Measures

Outcome	Result	p-value
PRIMARY Verbal Short Term Memory	43.7; 37.9; 43.6; 40.8	0.90
SECONDARY Overall Cognition as Measured on the MATRICS Battery	27.8; 23.2; 26.4; 25.4	0.76

Summary

This study is a six-week, randomized, placebo-controlled, fixed dose trial comparing cannabidiol Vs. placebo added to a stable dose of antipsychotic medications in patients diagnosed with schizophrenia.

Eligibility Criteria

Inclusion Criteria

Schizophrenia or Schizoaffective disorder (DSM-IV SCID-confirmed),

Exclusion Criteria

Women who are pregnant, nursing or unwilling to use appropriate birth control measures during study participation.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00588731). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.